Literature DB >> 26225175

XGEVA(®) (denosumab).

.   

Abstract

Entities:  

Year:  2015        PMID： 26225175      PMCID： PMC4479663     

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  2 in total

1.  Guidelines for the management of castrate-resistant prostate cancer.

Authors:  Fred Saad; Sebastien J Hotte
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

2.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.